Brisbane, California, USA | July 21, 2026
Nurix Therapeutics announced the official closing of its previously announced global collaboration agreement with Roche following the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. The agreement establishes a broad partnership to co-develop and co-commercialize bexobrutideg (NX-5948), an investigational Bruton’s tyrosine kinase (BTK) degrader, across malignant hematology, immunology, and neurology indications. Under the terms of the collaboration, Nurix will receive an upfront payment of $700 million and is eligible to earn up to $2.3 billion in development, regulatory, and commercial milestone payments. The companies will jointly execute one of the largest targeted protein degradation development programs to date, combining Nurix’s targeted protein degradation platform with Roche’s global clinical development and commercialization capabilities to accelerate the advancement of bexobrutideg for patients with significant unmet medical needs.
Collaboration Establishes Broad Global Development and Commercial Framework
The strategic alliance outlines an extensive co-development and commercialization structure designed to maximize the clinical and commercial potential of bexobrutideg. Development costs will be shared, with Roche funding 60% and Nurix contributing 40%, while the companies will equally share profits and losses from commercialization within the United States. Both organizations will jointly commercialize the therapy across all approved U.S. indications, whereas Roche will lead commercialization internationally, with Nurix receiving royalties ranging from the low- to high-teens on ex-U.S. sales. The collaboration will support an expansive clinical development strategy covering chronic lymphocytic leukemia (CLL), additional B-cell malignancies, multiple sclerosis (MS), and chronic spontaneous urticaria (CSU), reflecting the broad therapeutic potential of BTK degradation across oncology, autoimmune, and neurological diseases.
Bexobrutideg Advances as a Potential Best-in-Class BTK Degrader
Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, highly selective small-molecule BTK degrader designed using targeted protein degradation technology, an emerging drug discovery approach that eliminates disease-causing proteins rather than simply inhibiting their activity. The candidate is currently being evaluated in multiple clinical programs, including the DAYBreak CLL-201 pivotal Phase 2 trial for relapsed or refractory chronic lymphocytic leukemia and the NX-5948-301 Phase 1a/1b study in patients with relapsed or refractory B-cell malignancies. Additional studies include the Phase 3 DAYBreak CLL-306 trial, comparing bexobrutideg with pirtobrutinib, as well as a Phase 1/2 combination study evaluating the therapy alongside venetoclax, with or without an anti-CD20 antibody. A new tablet formulation is also being assessed in healthy volunteers to support future expansion into immunology and neurology indications.
Advertisement
Strategic Alliance Strengthens Leadership in Targeted Protein Degradation
According to Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Nurix Therapeutics, the Roche collaboration represents a transformational milestone for both the company and the rapidly evolving field of targeted protein degradation, enabling accelerated development of what Nurix believes could become one of the most ambitious degrader medicine programs undertaken to date. The collaboration combines Roche’s extensive global infrastructure with Nurix’s proprietary AI-integrated discovery engine and expertise in E3 ligase biology, supporting the development of innovative therapies for cancer and autoimmune diseases. Beyond bexobrutideg, Nurix continues to advance a growing pipeline of targeted protein degraders through both wholly owned programs and strategic collaborations with companies including Gilead Sciences, Sanofi, and Pfizer. The completion of the Roche partnership further strengthens Nurix’s position as a leading innovator in next-generation degrader therapeutics while expanding opportunities to deliver novel treatment options across oncology, immunology, and neurology.
Source: Nurix Therapeutics press release
